With the recent trials such as SELECT and STEP-HFpEF demonstrating benefits of GLP1-agonists in terms of CV risk reduction and improved exercise function, have you begun to incorporate this class of medications into routine CV health maintenance for patients with HFpEF and/or pre-existing CAD?

Answer from: at Community Practice

I would strongly support the use of this medication. The biggest challenge is insurance coverage. When would it be approved by insurance and how many hoops we will need to jump before they approve it?

Comments

at Sparrow Thoracic Cardiovascular Institute
Agree, insurance coverage is a problem. Only cover...

at Mercy Health The Heart Institute Fairfield
The issue lies in insurance companies categorizing...

at Buxmont Cardiology Associates
Yes, and my office staff is rebelling!

Answer from: at Community Practice

Established CV disease listening to the podcast MI, stroke or CHF, and BMI greater than 27 were inclusion criteria and reported benefits. I am not certain if hypertensive heart disease qualifies in this category (being cardiovascular disease and with high prevalence of HFpEF) and if it does, ...

Please select the option that best describes you:

With the recent trials such as SELECT and STEP-HFpEF demonstrating benefits of GLP1-agonists in terms of CV risk reduction and improved exercise function, have you begun to incorporate this class of medications into routine CV health maintenance for patients with HFpEF and/or pre-existing CAD?

Related Questions